Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis
NCT06461299
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
9
Enrollment
OTHER
Sponsor class
Conditions
Perioral Dermatitis
Interventions
DRUG:
Seysara Oral Product
Sponsor
The Dermatology Institute of Boston